Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

BACKGROUND: CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in treating relapsed or refractory pediatric B-lineage acute lymphoblastic leukemia (B-ALL). However, poor results are obtained when the same product is reused in patients who relapse after CAR-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenjie, Ding, Lixia, Shi, Wenhua, Wan, Xinyu, Yang, Xiaomin, Yang, Jing, Wang, Tianyi, Song, Lili, Wang, Xiang, Ma, Yani, Luo, Chengjuan, Tang, Jingyan, Gu, Longjun, Chen, Jing, Lu, Jun, Tang, Yanjing, Li, Benshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031882/
https://www.ncbi.nlm.nih.gov/pubmed/36949487
http://dx.doi.org/10.1186/s12967-023-04019-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031882/
https://www.ncbi.nlm.nih.gov/pubmed/36949487
http://dx.doi.org/10.1186/s12967-023-04019-4

Ejemplares similares